作者:Tao Wu、Advait Nagle、Tomoyo Sakata、Kerstin Henson、Rachel Borboa、Zhong Chen、Kelli Kuhen、David Plouffe、Elizabeth Winzeler、Francisco Adrian、Tove Tuntland、Jonathan Chang、Susan Simerson、Steven Howard、Jared Ek、John Isbell、Xianming Deng、Nathanael S. Gray、David C. Tully、Arnab K. Chatterjee
DOI:10.1016/j.bmcl.2009.10.050
日期:2009.12
Screening our in-house compound collection using a cell based Plasmodium falciparum proliferation assay we discovered a known pan- kinase inhibitor scaffold as a hit. Further optimization of this series led us to a novel benzamide scaffold which was devoid of human kinase activity while retaining its antiplasmodial activity. The evolution of this compound series leading to optimized candidates with good cellular potency against multiple strains as well as decent in vivo profile is described in this Letter. (C) 2009 Elsevier Ltd. All rights reserved.